BEGIN:VCALENDAR VERSION:2.0 METHOD:PUBLISH PRODID:-//ACC//Meetings//EN BEGIN:VTIMEZONE TZID:Eastern Standard Time BEGIN:STANDARD DTSTART:16011101T020000 RRULE:FREQ=YEARLY;BYDAY=1SU;BYMONTH=11 TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:Eastern Standard Time END:STANDARD BEGIN:DAYLIGHT DTSTART:16010301T020000 RRULE:FREQ=YEARLY;BYDAY=2SU;BYMONTH=3 TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:Eastern Daylight Time END:DAYLIGHT END:VTIMEZONE BEGIN:VEVENT DESCRIPTION:\n\n\n\nWebinar Overview\nIn this webinar\, Katherine Crawford\ , PharmD\, BCCP\, AACC\, and Katherine S. Dodd\, DO\, FACC\, discuss addit ional and new pharmacological therapies to consider when treating worsenin g Heart Failure (HF). In particular\, they review treatments found to sign ificantly reduce rehospitalizations\, such as SGLT2i\, ARNI\, and ferric c arboxymaltose\, as well as the newer finerenone and vericiguat.\nThis webi nar is part of the larger Managing HF Across the Spectrum: From Recognizin g Symptoms to Implementing Appropriate Treatment online course\, supported by Bayer AG.\nKey Objectives/Learning Outcomes:\nEvaluate the epidemiolog y\, risk factors\, comorbidities\, and community aspects associated with H F to determine best practices for care.\nDistinguish pathophysiologic char acteristics of current classifications of phenotypes when diagnosing HF to analyze the best HF risk stratification\, prevention\, and management str ategies.\nIncorporate GDMT\, newer therapies\, and interprofessional team strategies into treatment care plans for the management of HF to improve c are coordination\, communication\, and patient outcomes.\n\nWebinar Record ing\n\n\n\n\nWebinar Participants\nKatherine Crawford\, PharmD\, BCCP\, AA CC\nKatherine S. Dodd\, DO\, FACC\n\nCredit Information\nNo credit is bein g offered for this webinar.\n\n\n\n\n\n .videoWrapper {\n position: relative\;\n padding-bottom: 56.25%\; /* 16:9 */\n padding-top: 25px \;\n height: 0\;\n }\n .videoWrapper iframe {\n position: abso lute\;\n top: 0\;\n left: 0\;\n width: 100%\;\n height: 100%\; \n }\n\n DTEND;TZID=Eastern Standard Time:20251205T083600 DTSTAMP:20260409T210337Z DTSTART;TZID=Eastern Standard Time:20251205T082100 LOCATION:Online - Eastern Time (ET) SEQUENCE:0 SUMMARY:Additional Therapies For Worsening HF: Medications and Devices UID:9628c402-0bde-48f8-bda0-1980e272227f@acc.org X-ALT-DESC;FMTTYPE=text/html:\n
\n
\n\n

Webinar Over view

\n

In this webinar\, Katherine C rawford\, PharmD\, BCCP\, AACC\, and Katherine S. Dodd\, DO\, FACC\, discuss additional and new pharmacological therapies to consider when treating worsening Heart Failure (HF). In particular\, th ey review treatments found to significantly reduce rehospitalizations\, su ch as SGLT2i\, ARNI\, and ferric carboxymaltose\, as well as the newer fin erenone and vericiguat.

\n

This webinar is part of the larger Managing HF Across the Spectrum: From Recognizin g Symptoms to Implementing Appropriate Treatment online course\, supported by Bayer AG.

\n

Key Objectives/Learn ing Outcomes:

\n
  1. Evaluate the epidemiolo gy\, risk factors\, comorbidities\, and community aspects associated with HF to determine best practices for care.
    2. \n
  2. Distinguish pathophysio logic characteristics of current classifications of phenotypes when diagno sing HF to analyze the best HF risk stratification\, prevention\, and mana gement strategies.
    3. \n
  3. Incorporate GDMT\, newer therapies\, and inte rprofessional team strategies into treatment care plans for the management of HF to improve care coordination\, communication\, and patient outcomes .
\n\n

Webinar Recording

\n< div class="videoWrapper">\n\n
\n\n

Webinar Participants

\n

Katherine C rawford\, PharmD\, BCCP\, AACC
\nKatherine S. Dodd\, DO\, FACC

\n\n

Credit Information

\n

No credit is being offered for this webinar.

\n\n
\n\n\n